- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06768671
중등도~중증 화농한선염(VELA-TEEN) 청소년을 대상으로 피하 소넬로키맙의 약동학 및 안전성을 평가하기 위한 공개 단일군 연구
활동성 중등도 내지 중증 화농성 한선염이 있는 연구 포함 당시 ≥12~17세 청소년을 대상으로 피하 소넬로키맙의 약동학 및 안전성을 평가하기 위한 공개, 단일군 연구
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Arkansas
-
North Little Rock, Arkansas, 미국, 72117
- Clinical Site
-
-
California
-
Stanford, California, 미국, 94304
- Clinical Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- Clinical Site
-
-
Florida
-
Hollywood, Florida, 미국, 33201
- Clinical Site
-
Miami, Florida, 미국, 33136
- Clinical Site
-
-
Georgia
-
Macon, Georgia, 미국, 31217
- Clinical Site
-
Sandy Springs, Georgia, 미국, 30328
- Clinical Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Clinical Site
-
-
Indiana
-
Columbus, Indiana, 미국, 47201
- Clinical Site
-
-
Kentucky
-
Murray, Kentucky, 미국, 42071
- Clinical Site
-
-
Michigan
-
Waterford, Michigan, 미국, 48328
- Clinical Site
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58103
- Clinical Site
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Clinical Site
-
-
Texas
-
Dallas, Texas, 미국, 75246
- Clinical Site
-
Dallas, Texas, 미국, 75390-8575
- Clinical Site
-
San Antonio, Texas, 미국, 78218
- Clinical Site
-
-
Virginia
-
Norfolk, Virginia, 미국, 23502
- Clinical Site
-
-
Washington
-
Seattle, Washington, 미국, 98105
- Clinical Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participants must be between ≥12 and ≤17 years of age at the time of signing the informed consent.
- Participants who are diagnosed with HS as determined by the investigator and have a history of signs and symptoms of HS for ≥6 months before signing the informed consent.
- Participants who have moderate to severe HS as determined by the refined Hurley staging (Stages IB and IC, IIB and IIC, and III).
- Participants who have had an inadequate response to appropriate systemic antibiotics for treatment of HS .
- Participants must be up to date with age-appropriate vaccine requirements 8 weeks prior to entry in the study.
- Participants with a body weight of ≥ 40 kg.
Exclusion Criteria:
- Participants with a known hypersensitivity to sonelokimab or any of its excipients.
- Participants with a draining fistula count of ≥20 at the Screening Visit.
- Participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of HS.
- Participants with underlying conditions that, in the opinion of the investigator, potentially compromise the participant and/or places the participant at unacceptable risk.
- Participants who have history or concurrent clinically significant medical conditions or any other reason, including any physical, psychological, or psychiatric condition, that in the opinion of the investigator would compromise the safety or interfere with participation in the study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk.
- Participants with any other skin disease or other medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of HS.
- Participants with a confirmed or suspected diagnosis of inflammatory bowel disease.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: sonelokimab
Subjects will receive sonelokimab 120mg subcutaneously (SC) as an induction regimen of 4 doses, followed by sonelokimab SC every 4 weeks maintenance dose starting at Week 8 |
Open label |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pharmacokinetics (PK) of sonelokimab in adolescents
기간: Week 24
|
PK (trough concentrations) of sonelokimab over 24 weeks of treatment |
Week 24
|
|
Adverse events (AEs) following treatment with sonelokimab in adolescents
기간: Week 24
|
Incidence, relatedness, severity and seriousness of all AEs over 24 weeks of treatment from baseline |
Week 24
|
|
Discontinuation of sonelokimab treatment due to AEs
기간: Week 24
|
Number of participants discontinued from sonelokimab treatment due to AE over 24 weeks of treatment from baseline |
Week 24
|
|
Clinically significant changes in clinical laboratory parameters
기간: Week 24
|
Number of participants with clinically significant changes in hematology, biochemistry and urinalysis from baseline |
Week 24
|
|
Clinically significant changes in vital signs
기간: Week 24
|
Number of participants with clinically significant changes in vital signs from baseline |
Week 24
|
|
Clinically significant changes in standard 12-lead electrocardiogram (ECG) intervals
기간: Week 24
|
Number of participants with clinically significant changes in 12-lead ECG intervals from baseline |
Week 24
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Hidradenitis Suppurativa Clinical Response (HiSCR)75
기간: Week 24
|
Percentage of participants achieving a HiSCR75 response over time |
Week 24
|
|
Hidradenitis Suppurativa Clinical Response (HiSCR) 50
기간: Week 24
|
Percentage of participants achieving a HiSCR50 response over time |
Week 24
|
|
International Hidradenitis Suppurativa Severity Score System (IHS4)
기간: Week 24
|
Absolute change in IHS4 score over time |
Week 24
|
|
Children's Dermatology Life Quality Index (CDLQI)
기간: Week 24
|
Percentage of participants achieving a CDLQI total reduction of ≥2.5 over time among participants with a baseline CDLQI ≥2.5 |
Week 24
|
|
Numerical Rating Scale (NRS) 30
기간: Week 24
|
Percentage of participants achieving a ≥30% reduction and a ≥2-unit reduction over time in the NRS30 for pain in PGA among participants with a baseline NRS ≥3 |
Week 24
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- M1095-HS-304
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .